Merck KGaA Stock
€138.50
Your prediction
Merck KGaA Stock
Pros and Cons of Merck KGaA in the next few years
Pros
Cons
Performance of Merck KGaA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Merck KGaA | -0.650% | -2.381% | 4.224% | 23.036% | 13.982% | -6.974% | -18.670% |
| Bayer AG | 0.660% | -2.259% | 37.697% | 81.140% | 34.496% | -1.719% | -1.680% |
| Biogen Inc. | -0.070% | 0.779% | 6.295% | 59.965% | 22.603% | -25.800% | -38.524% |
| BioMarin Pharmaceutical Inc. | -1.450% | -0.652% | 7.113% | 4.204% | 1.768% | -32.323% | -26.400% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Merck (US Symbol: MKGAF) operates within the dynamic pharmaceutical industry, and its financial performance reflects a blend of growth potential and certain challenges. With a solid market capitalization of approximately €72.1 billion and a range of strategic investments, Merck exhibits an underlying strength capable of sustaining its operations and exploring future growth avenues. Analyzing the financials provides a deeper understanding of both the strengths and weaknesses that shape the company's market position.
Strong Revenue Generation
Merck's total revenue for the most recent year stands at approximately €20.82 billion. This solid revenue base underscores the company's ability to generate substantial cash flow, crucial for funding operational activities, research and development (R&D), and other strategic initiatives.
Solid Profit Margins
The profit margin is reported at 13.07%, indicating that Merck is successful in converting a significant portion of its sales into net income. This efficiency is essential in maintaining a competitive edge within an industry characterized by high research and development costs.
Comments
News
Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting
Key Points
- Interested in Achieve Life Sciences, Inc.? Here are five stocks we like better.
- Achieve Life Sciences held its 2026 annual meeting and presented a slate of nine directors for
Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.
GLP-1 drugs are more popular than ever. This week, polling organization Gallup reported that 11% of U.S. adults are currently taking GLP-1 medications for weight loss, which is a huge jump from the
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Choosing between Bristol Myers Squibb (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ) means deciding whether you prefer a pure-play pharmaceutical company trading at a deep discount or a diversified